SGLT2 Inhibitors Expand from Diabetes to Heart Failure and Kidney Disease as Foundational Cardiorenal Therapy
Words by Yuriy Poteshkin, MD, phD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors emerged as foundational therapies for heart failure and chronic kidney disease regardless of diabetes status, with 2025 bringing definitive evidence...
Dec 31, 2025Read more
trends 2025SGLT2 inhibitorsheart failure
